Although primary endpoint did not reach statistical significance.

Progress studied 360 sufferers with SHPT and detectable CAC who had been randomised to open label treatment with cinacalcet plus low-dose supplement D or even to flexible vitamin D therapy. In both groups, calcium-based phosphate binders exclusively were used, and the therapeutic focus on for PTH was 150-300 pg/mL. The primary endpoint for ADVANCE evaluated the %age alter in Agatston CAC rating from baseline to week 52.Related StoriesScientists suggest that Alzheimer's disease should be treated separatelyLewy Body Composite Risk Score detects LBD and Parkinson's disease dementia in three minutesSynAgile announces excellent results from Phase 2a trial of continuous intraoral LD/CD therapy We are excited to introduce the Nurelin program at the conference today, and to provide an update on the previous preclinical and clinical studies that have resulted in our first Phase 2/3 study of Nurelin in Parkinson’s patients who knowledge levodopa-induced dyskinesia, said Dr.